Clinical trials: CVD - Cardiovascular Disease
Newly Diagnosed Multiple Myeloma
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have…
- Trial name
- NCT03733691
- Testing
- Ixazomib, Lenalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncotherapeutics
Hypertension
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination
To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy
- Trial name
- NCT00618774
- Testing
- telmisartan40/amlodipine5, telmisartan80/amlodipine5
- Where
- 7 sites in Japan
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin
The aim of this study is to assess the efficacy, safety and performance of LAmbre left atrial appendage closure system in patients with non-valvular atrial fibrillation who cannot be treated with Warfarin.
- Trial name
- NCT02029014
- Testing
- LAA closure system
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Hypertrophic Cardiomyopathy
A Trial of HRS-1893 in Healthy Volunteers
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
- Trial name
- NCT07033455
- Testing
- HRS-1893
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Atrial Fibrillation, Cardiac Arrhythmias
INSIGHT (R)XT. Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT
To describe the clinical indications for Reveal XT in diagnosis and continuous monitoring of arrhythmia and to explore the clinical applications and outcome of arrhythmia monitoring on patient care.
- Trial name
- NCT00680550
- Where
- 56 sites in Austria, Belarus and 14 more
- Volunteers
- 1,003 people
- Sponsor
- Medtronic BRC
Diabetic Foot Ulcer, Diabetic Foot
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).
- Conditions
- Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic
- Trial name
- CAMPAIGN (NCT06600724)
- Testing
- Standard of Care, EPIEFFECT, EPIXPRESS
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- MiMedx Group, Inc.
Waldenström Macroglobulinemia (WM)
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
- Trial name
- NCT02180724
- Testing
- Acalabrutinib (ACP-196)
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 107 people
- Sponsor
- Acerta Pharma BV
Hereditary Angioedema, Hereditary Angioedema Type I
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand…
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
- Trial name
- RAPIDe-3 (NCT06343779)
- Where
- 76 sites in United States, Argentina and 27 more
- Volunteers
- 134 people
- Sponsor
- Pharvaris Netherlands B.V.
Retinal Vein Occlusion, Macular Edema
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits.
- Trial name
- NCT01411696
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Allergan
Stroke
An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke
Study to evaluate the safety and efficacy of intravenous recombinant tissue Plasminogen Activator, alteplase, Actilyse® (rt-PA) (0.9 mg/kg) within 3 hours of symptom onset in acute ischemic stroke
- Trial name
- NCT02229890
- Testing
- alteplase
- Volunteers
- 593 people
- Sponsor
- Boehringer Ingelheim
Waldenström's Macroglobulinemia
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
- Trial name
- NCT02165397
- Testing
- Ibrutinib, Rituximab
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 181 people
- Sponsor
- Pharmacyclics LLC.
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Hypertension
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
- Trial name
- NCT00281580
- Testing
- Amlodipine 5 mg, Telmisartan 20 mg, Telmisartan 40 mg
- Where
- 136 sites in United States, Argentina and 3 more
- Volunteers
- 1,461 people
- Sponsor
- Boehringer Ingelheim
Intracranial Aneurysm
Safety & Performance of the World Medica World Diverter Embolization Device
The objective of this study is to investgiate the safety and clinical performance of the World Diverter Emoblization Device for the endovascular treatment of wide-neck (neck width ≥ 4 mm or dome-to-neck ratio <2) or fusiform…
- Trial name
- NCT07339358
- Testing
- Flow diverter implantation
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- World Medica USA, LLC
Bradycardia, Sinus Node Dysfunction
Safety and Performance Study of the INGEVITY Lead
The objective of this study is to gather data to establish the safety, performance and effectiveness of the INGEVITY pace/ sense leads.
- Trial name
- NCT01688843
- Testing
- INGEVITY lead
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,060 people
- Sponsor
- Boston Scientific Corporation
Healthy Volunteers
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers
- Trial name
- NCT05041543
- Testing
- NTX-101
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pinotbio, Inc.
Atrial Fibrillation
Use of Volta Medical AI-software During Atrial Fibrillation Ablation to Identify Patients Who May Need More Than Pulmonary Vein Isolation.
DISPLAY-AF is a prospective, multicenter, single-arm post-market clinical follow-up investigation designed to evaluate whether spatiotemporal dispersion areas identified by the Volta AF-Xplorer II artificial intelligence (AI)…
- Trial name
- DISPLAY-AF (NCT07807423)
- Testing
- Complete biatrial mapping
- Where
- 5 sites in France
- Volunteers
- 125 people
- Sponsor
- Volta Medical
Ischemic Stroke
Trevo® Retriever Registry Post Market Surveillance
The purpose of the Trevo® Retriever Registry is to collect real world performance data of the Trevo Retriever which is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic…
- Trial name
- NCT02040259
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 2,008 people
- Sponsor
- Stryker Neurovascular
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.